Repligen (RGEN) Aktie Kurs
Repligen Kurs
Intäkterna har vuxit med 23,2 % per år under de senaste 19 åren till 738,26 M USD. Vinst per aktie har minskat med 1,8 % per år under de senaste 18 åren. Repligens nettovinstmarginal ligger på 6,6 %, ned från 19,1 % för några år sedan. Analytikernas mediankursmål är 152,50 USD, vilket är under nuvarande kurs med 13,2 %. Av 27 analytiker ger 22 köpråd — den samlade bedömningen är Köp.
Repligen aktiekurs
Hämta dessa data via Eulerpool API
100 000 anrop/mån gratis · inget kreditkort
Repligen affärsmodell och aktieanalys
Vanliga frågor om Repligen-aktien
Repligen Corp's business model is centered around being a leading provider of products and services for the bioprocessing industry. The company focuses on developing and supplying innovative solutions that enhance the production of biologic drugs. Repligen offers a range of products including bioreactors, filtration systems, chromatography resins, and pre-packed columns. By offering these high-quality and reliable solutions, Repligen aims to support biopharmaceutical companies in improving their manufacturing processes, increasing productivity, and ensuring the quality of their products. Repligen Corp is dedicated to driving advancements in the bioprocessing industry by delivering exceptional products and services to its customers.
Repligen Corp is primarily active in the biotechnology and life sciences industries.
Some of the main competitors of Repligen Corp in the market include Thermo Fisher Scientific, Merck KGaA, Danaher Corporation, and GE Healthcare.
Repligen Corp is a prominent bioprocessing company with a rich history. Founded in 1981, Repligen initially focused on the development of diagnostic products and later expanded its scope to include bioprocessing technologies. Over the years, the company has made significant contributions to the life sciences industry, offering innovative solutions for biomanufacturing needs. Today, Repligen is recognized for its high-quality products and services, serving customers globally. With a commitment to advancing bioprocessing efficiency and productivity, Repligen continues to drive innovation in the field, supporting the development and manufacturing of biologics.
Repligen Corp has achieved several significant milestones. The company successfully completed the acquisition of Spectrum Laboratories in 2012, expanding its product portfolio and enhancing its market presence. In 2014, Repligen received FDA approval for its flagship bioprocessing product, Protein A, which revolutionized the purification of monoclonal antibodies. The company continued its growth by acquiring the business unit of Novavax Inc. in 2015, strengthening its position in the bioprocessing market. Repligen Corp also reached a partnership agreement with Navigo Proteins GmbH in 2019, allowing the development of new affinity ligands. These achievements demonstrate Repligen Corp's dedication to innovation and market leadership.
Repligen Corp is primarily present in several countries and regions. These include the United States, Europe, and Asia.
Repligen Corp is a leading bioprocessing company committed to enhancing biologic drug manufacturing processes. The company's corporate philosophy revolves around key values such as innovation, quality, and collaboration. Repligen Corp strives to provide cutting-edge solutions to improve productivity, efficiency, and consistency in bioproduction through its advanced technologies and expertise. With a focus on customer satisfaction and a passion for advancing bioprocessing technologies, Repligen Corp aims to empower customers and contribute to making biologic medicines more accessible for patients worldwide.
Analytiker sätter för närvarande ett genomsnittligt riktkurs på 152,00 USD för Repligen-aktien (median: 152,50 USD), vilket innebär −15,1 % mot senaste kurs. Konsensus baseras på 27 analytikerbetyg.
27 analytiker betygsätter för närvarande Repligen-aktien: 22 rekommenderar köp, 5 behåll och 0 sälj. För 2026 väntar sig analytiker att Repligen genererar intäkter på 846,27 M USD och vinst per aktie på 2,05 USD.
Omräknat till aktuell växelkurs handlas Repligen-aktien till 157,00 EUR (175,63 USD).
Repligen-aktien (RGEN) är noterad på 5 börser, bland annat: NASDAQ (RGEN), SIX (Zürich) (RGN.SW), Frankfurt (RGN.F), München (RGN.MU), Düsseldorf (RGN.DU).
Repligen Corp is a leading biotech company specializing in the research, development, and manufacturing of products for bioproduction and cell therapy. The company was founded in 1981 and is headquartered in Waltham, Massachusetts. Repligen Corp's business model is based on four different divisions: bioproduction, chromatography, short-term culture media, and cell therapy. These divisions offer a wide range of products for the research and development community as well as the biopharmaceutical industry. The bioproduction division of Repligen Corp offers a variety of products for the production of recombinant proteins, antibodies, and other therapeutics. These include HGGE and Protein-A affinity resins, the TangenX® membrane separation portfolio, and the XCell™ ATF system for perfusion. The chromatography division of Repligen Corp offers a wide range of products for the purification of proteins and other biologics. These include protein-A affinity resins, reversed-phase resins, HIC and ion exchange resins, and more. The short-term culture media division of Repligen Corp specializes in the development of media for cell cultivation. These include the OptiCHO™, OptiPEAK TiterMAX®, and CellBoost™ portfolios. The cell therapy division of Repligen Corp offers strictly regulated products for clinical applications in cell therapy. These include Syntheglas™ peptides and SAVI™ cell therapy products for the treatment of inflammatory diseases in the gastrointestinal tract. Repligen Corp also offers services and support for its products, including technical consulting and support as well as product training. The company works closely with its customers to ensure that its products meet the specific requirements of the research and biopharmaceutical industry. Overall, Repligen Corp has a strong business model based on the development of innovative products for bioproduction and cell therapy. The company is committed to advancing the development of its products and actively participating in the expansion of the bioproduction industry. Answer: Repligen Corp is a biotech company specializing in the research, development, and manufacturing of products for bioproduction and cell therapy. They offer a range of products for protein production, protein purification, cell cultivation, and cell therapy. The company provides services, support, and product training and aims to contribute to the growth of the bioproduction industry.
Omsättningen för förväntad Repligen är 846,27 M USD. Denna siffra baseras på aktuella finansiella data och återspeglar företagets affärsresultat.
Nettovinsterna för förväntad Repligen är 115,98 M USD. Nettovinsterna återspeglar företagets lönsamhet efter avdrag för alla utgifter.
Kurs-vinstkvoten (P/E) för Repligen är för närvarande 85,59. P/E-talet jämför den aktuella aktiekursen med vinsten per aktie och hjälper investerare att bedöma värderingen av Repligen-aktien.
Kurs-försäljningskvoten (P/S) för Repligen är för närvarande 11,73. P/S-talet jämför börsvärdet med den årliga omsättningen och fungerar som ett värderingsmått för Repligen-aktien.
Eulerpool Quality Score för Repligen är 4/10.
ISIN för Repligen är US7599161095. ISIN (International Securities Identification Number) är en globalt unik identifierare för värdepapper.
WKN för Repligen är 870980. WKN (Wertpapierkennnummer) är ett sexsiffrigt tyskt identifieringsnummer för värdepapper.
Tickern för Repligen är RGEN. Tickersymbolen används för att handla Repligen-aktier på börsen.
Repligen aktie
Repligen Jämförbar grupp
Repligen Ticker
Repligen FIGI
Alla nyckeltal och djupgående analys av Repligen
Vår aktieanalys av Repligen-aktien innehåller viktiga finansiella nyckeltal som omsättning, vinst, P/E-tal, P/S-tal, EBIT samt information om utdelningen. Dessutom granskar vi aspekter såsom aktier, börsvärde, skulder, eget kapital och skuldförbindelser hos Repligen. Om du söker mer detaljerad information om dessa ämnen erbjuder vi på våra undersidor ingående analyser: